Trial Profile
Phase I dose-escalation study of oral administration of Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in patients with solid tumour
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Abexinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Servier
- 09 Aug 2013 New trial record